SCHEMBL7544254

SCHEMBL7544254

CC(=O)NS(=O)(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
DHFR P00374 1/20 0.65
TSHR P16473 1/20 0.65
AKR1C2 P52895 1/20 0.55
AKR1C1 Q04828 1/20 0.55
PKM P14618 1/20 0.54
POLB P06746 1/20 0.54
HSD17B10 Q99714 1/20 0.54
F2 P00734 1/20 0.53
PRSS1 P07477 1/20 0.53
PRSS2 P07478 1/20 0.53
PRSS3 P35030 1/20 0.53
CA12 O43570 2/20 0.52
CA1 P00915 2/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52
CA3 P07451 1/20 0.52
CA6 P23280 1/20 0.52
CYP2C19 P33261 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2039560 0.86 TSHR (0.67) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL4071822 0.83 SMN1; SMN2 (0.68) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL7899812 0.83 SMN1; SMN2 (0.62) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL209632 0.82 DHFR (0.66) SMN1; SMN2TDP1DHFRTSHRAKR1C2
SCHEMBL19629792 0.81 F2 (0.50) TDP1TSHRF2PRSS1PRSS2
SCHEMBL19627411 0.80 ALDH1A1 (0.68) TDP1F2PRSS1PRSS2PRSS3
SCHEMBL19627396 0.80 F2 (0.49) TSHRF2PRSS1PRSS2PRSS3
SCHEMBL5931251 0.80 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRPKM
SCHEMBL1764031 0.80 SMN1; SMN2 (0.57) SMN1; SMN2TSHRF2PRSS1PRSS2
SCHEMBL7541831 0.80 SMN1; SMN2 (0.69) SMN1; SMN2TDP1DHFRTSHRAKR1C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof ENANTA PHARMACEUTICALS, INC. 2017-11-23 US disclosed
US-20020094993-A1 Compositions for repelling crawling insects S.C. JOHNSON & SON, INC. 2002-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334894-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, NR1H4 SMN1; SMN2 4675/4885TDP1 3945/4885DHFR 1038/4885
US-20170333399-A1 Isoxazole Derivatives as FXR Agonists and Methods of Use Thereof SLC10A1, FXR1, SLC10A2 SMN1; SMN2 4664/4885TDP1 3899/4885DHFR 1016/4885
US-20020094993-A1 Compositions for repelling crawling insects ACHE, DDT, GAP43 SMN1; SMN2 2971/4885TDP1 3063/4885DHFR 4154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.